Novartis Faces Strict Pharmacy Oversight In $390M Deal
Novartis on Friday made detailed admissions about its sales strategies with specialty pharmacies and agreed to sweeping federal oversight of its relationships with the controversial dispensers, capping off a mammoth False...To view the full article, register now.
Already a subscriber? Click here to view full article